Arcus Biosciences Inc (RCUS) - Total Liabilities
Based on the latest financial reports, Arcus Biosciences Inc (RCUS) has total liabilities worth $538.00 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore RCUS operating cash flow to assess how effectively this company generates cash.
Arcus Biosciences Inc - Total Liabilities Trend (2016–2024)
This chart illustrates how Arcus Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Check Arcus Biosciences Inc (RCUS) asset resilience to evaluate the company's liquid asset resilience ratio.
Arcus Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Arcus Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shenzhen SDG Information Co Ltd
SHE:000070
|
China | CN¥5.19 Billion |
|
Kitron ASA
OL:KIT
|
Norway | Nkr427.40 Million |
|
Shanghai Pret Composites
SHE:002324
|
China | CN¥8.21 Billion |
|
Wallenstam AB (publ)
ST:WALL-B
|
Sweden | Skr42.65 Billion |
|
Soulbrain Co. Ltd
KQ:357780
|
Korea | ₩298.95 Billion |
|
Meitu Inc
F:M5U
|
Germany | €1.93 Billion |
|
Investco Holding AS
IS:INVES
|
Turkey | TL2.26 Billion |
|
A-Zenith Home Furnishings Co Ltd
SHG:603389
|
China | CN¥904.28 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Arcus Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Arcus Biosciences Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Arcus Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Arcus Biosciences Inc (2016–2024)
The table below shows the annual total liabilities of Arcus Biosciences Inc from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $665.00 Million | +5.06% |
| 2023-12-31 | $633.00 Million | -7.99% |
| 2022-12-31 | $688.00 Million | -8.32% |
| 2021-12-31 | $750.45 Million | +177.96% |
| 2020-12-31 | $269.99 Million | +587.55% |
| 2019-12-31 | $39.27 Million | -1.79% |
| 2018-12-31 | $39.98 Million | +9.19% |
| 2017-12-31 | $36.62 Million | +257.53% |
| 2016-12-31 | $10.24 Million | -- |
About Arcus Biosciences Inc
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develop… Read more